These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20224850)

  • 1. The ultimate anticoagulants?
    Cardiovasc J Afr; 2010; 21(1):55-6. PubMed ID: 20224850
    [No Abstract]   [Full Text] [Related]  

  • 2. New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty.
    Eikelboom JW; Weitz JI
    BMJ; 2011 Jan; 342():c7270. PubMed ID: 21245113
    [No Abstract]   [Full Text] [Related]  

  • 3. [Bleeding and surgery in the treatment with new oral anticoagulants. The management can be complicated by the lack of specific antidotes].
    Dalén M; Hjemdahl P; Holmström M; Ivert T
    Lakartidningen; 2014 Jun 11-17; 111(24):1064-8. PubMed ID: 25129916
    [No Abstract]   [Full Text] [Related]  

  • 4. Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
    Blann AD
    Br J Biomed Sci; 2014; 71(4):158-67. PubMed ID: 25562993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
    Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
    Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
    [No Abstract]   [Full Text] [Related]  

  • 7. [New clinical perspectives in the management of oral direct anticoagulant agents].
    Marco P; Zamorano JL; Chana F; Llau JV
    Med Clin (Barc); 2014 Feb; 142(4):171-8. PubMed ID: 23866969
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
    Lane DA; Wood K
    Circulation; 2015 Apr; 131(16):e412-5. PubMed ID: 25901074
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.
    Baumann Kreuziger LM; Reding MT
    Thromb Res; 2013 Aug; 132(2):e161-3. PubMed ID: 23916381
    [No Abstract]   [Full Text] [Related]  

  • 10. Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery?
    Rosencher N; Bellamy L; Arnaout L
    Arch Cardiovasc Dis; 2009 Apr; 102(4):327-33. PubMed ID: 19427610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dabigatran and rivaroxaban, new oral anticoagulants for the treatment of venous thromboembolism].
    Ordovás Baines JP
    Farm Hosp; 2009; 33(3):123-4. PubMed ID: 19712595
    [No Abstract]   [Full Text] [Related]  

  • 12. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
    Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In the pipeline: new oral anticoagulants for the prevention of venous thromboembolism.
    Farley TM; Lewis D; Macaulay TE
    Orthopedics; 2009 Jan; 32(1):35. PubMed ID: 19226034
    [No Abstract]   [Full Text] [Related]  

  • 14. Bleeding and antidotes in new oral anticoagulants.
    Majeed A; Schulman S
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
    Akwaa F; Spyropoulos AC
    Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.
    Baglin T; Keeling D; Kitchen S;
    Br J Haematol; 2012 Nov; 159(4):427-9. PubMed ID: 22970737
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel oral anticoagulants--key messages for the angiologist.
    Haas S; Spannagl M; Schellong SM
    Vasa; 2012 May; 41(3):177-91. PubMed ID: 22565619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
    Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
    Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New oral anticoagulant agents - general features and outcomes in subsets of patients.
    Schulman S
    Thromb Haemost; 2014 Apr; 111(4):575-82. PubMed ID: 24452881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New direct oral anticoagulants and venous thromboprophylaxis].
    Degirmenci SE; Steib A
    Rev Prat; 2013 Sep; 63(7):976-9. PubMed ID: 24167901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.